Additional blood sample clinical trials
Additional blood sample is named as an intervention in 2 current clinical trials in our France register. 2 are recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is University Hospital, Bordeaux (1). The most-studied condition is Chronic Graft Versus Host Disease.
Patient leaflets for Additional blood sample
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Additional blood sample
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Role of Viscoelastometric Testing in the Development and Validation of a Clinical-biological Score for Predicting Bleeding in Patients With Malignant Haematological Disorders and Severe Thrombocytopenia
NCT07653672 · ClinicalTrials.gov ↗ · Thrombocytopenia, Platelet Transfusion, Haemorrhage
|
Observational | Recruiting | Centre Hospitalier Annecy Genevois | France |
|
Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD)
NCT06247150 · ClinicalTrials.gov ↗ · Chronic Graft Versus Host Disease
|
Not applicable | Recruiting | University Hospital, Bordeaux | France |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Additional blood sample
5 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| University Hospital, Bordeaux | 1 |
| Centre Hospitalier Annecy Genevois | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in France | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Additional blood sample trials
How many clinical trials are testing Additional blood sample?
2 current trials in our France register name Additional blood sample as a drug or biological intervention, as of the registry sync on 23 October 2026. Completed and withdrawn studies are not counted.
Are Additional blood sample trials recruiting patients?
Yes. 2 of the 2 trials are recruiting: 2 with sites in France. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Additional blood sample clinical trials?
University Hospital, Bordeaux (1) and Centre Hospitalier Annecy Genevois (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Additional blood sample works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Additional blood sample works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Additional blood sample (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 23 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.